http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2006082821-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2006-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-WO2006082821-A1 |
| titleOfInvention | Preventive or therapeutic agent for diseases involving herpes virus |
| abstract | PROBLEM TO BE SOLVED: To provide a pharmaceutical composition useful for prevention or treatment of various diseases associated with pharmaceuticals, particularly herpesviridae virus infection. The present invention relates to an anti-herpesvirus agent characterized by combining a helicase-primase inhibitor and a polymerase inhibitor. The anti-herpesvirus agent of the present invention achieves a significantly superior anti-herpesvirus action compared to conventional administration of a polymerase inhibitor alone by combining a helicase-primase inhibitor with a different mechanism of action with a polymerase inhibitor. There is something to do. Therefore, it is particularly effective in cases where a sufficient therapeutic effect cannot be achieved with a polymerase inhibitor alone. In addition, since it is possible to keep the doses of both agents low, it is possible to perform treatment with a lower adverse effect of concern. [Selection figure] None |
| priorityDate | 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 509.